Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameChinares Pharma
Stock Code03320
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國領先的綜合醫藥公司,從事研發、製造、分銷及零售種類繁多的醫藥及其他營養保健品,主要經營製藥、醫藥分銷及藥品零售三大分部。
Listing Date2016-10-28
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港灣仔港灣道26號華潤大廈41樓4104-05室
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.crpharm.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 9.10 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2016-10-17 to 2016-10-20
Global Offering Shares1,543,141,500 shares
HK Public Offer Shares (Initial)77,158,000 shares (5.0%)
Public Offer Lots (Initial)154,316lots (Pool A77,158lots,Pool B77,158lots)
International Placing Shares (Initial)1,465,983,500 shares (95.0%)
Offer Ratio~5.0%
Total Shares Post-IPO6,172,565,961 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share12.7%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 14,042,587,650

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 29.66B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約港幣6,082.2百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 377,100,000
Listing Expenses / Funds Raised~2.69%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 HKD
Income Statement
Item 2013201420152016-06
Revenue 116,950,696135,749,180146,568,10575,615,523
Cost of sales -96,801,611-114,259,158-123,369,243-63,862,413
Gross profit 20,149,08521,490,02223,198,86211,753,110
Other income and gains, net 756,322917,5211,002,378451,866
Selling and distribution expenses -8,423,115-8,800,154-10,111,546-4,968,248
Administrative expenses -3,673,505-4,246,773-3,844,892-1,743,811
Operating profit 8,683,6479,057,37210,100,7575,117,870
Net finance costs -1,770,734-2,134,599-2,050,462-889,096
Share of associates and JVs 49,05464,64058,22431,832
Profit before tax 6,912,9136,922,7738,050,2954,228,774
Income tax expense -1,458,286-1,430,902-1,968,061-1,048,264
Profit for the year 5,454,6275,491,8716,082,2343,180,510
Profit attributable to owners 2,639,5172,645,9402,850,0761,636,069
Balance Sheet
Item 2013201420152016-06
Cash and cash equivalents 15,175,38713,417,62412,378,60610,475,006
Trade and bills receivables 38,044,58845,189,02847,514,24953,428,379
Inventories 12,198,12215,711,48015,251,98316,206,052
Total current assets 68,797,83184,277,19188,856,87787,986,880
Total assets 104,823,067121,797,602127,148,599125,916,533
Total current liabilities 58,897,90765,472,48872,223,79671,190,338
Total liabilities 72,174,37384,647,14887,303,03486,214,140
Total equity 32,648,69437,150,45439,845,56539,702,393
Equity attributable to owners 17,988,25520,516,31922,502,23522,597,665
Interest-bearing borrowings 31,215,59737,262,84637,218,33837,728,447
Cash Flow Statement
Item 2013201420152016-06
Net cash from operating activities 4,102,1574,186,7225,988,790611,572
Net cash from investing activities -5,788,721-7,979,088-3,919,222-426,924
Net cash from financing activities 4,008,6693,090,312-1,554,283-2,527,495
Net increase in cash 2,322,105-702,054515,285-2,342,847
Depreciation of PP&E 942,4211,048,0001,090,257564,676
Amortisation of intangible assets 191,316228,601198,358110,635
Purchase of PP&E -2,264,144-2,015,446-1,246,284-473,531
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 9.01
First Day OpenHK$ 9.1
First Day Change-0.99%
First Day Volume119767000.0
First Day Turnover1081380000.0
Use of Proceeds
1、約45%的所得款項凈額或約港幣6,288.4百萬元預期用作戰略收購,擴大制藥及醫藥分銷業務; 2、約15%的所得款項凈額或約港幣2,096.1百萬元預期用作在中國建立更多的醫藥分銷業務的先進物流中心及倉庫; 3、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作投資于研發平臺; 4、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作改進及升級我們的信息技術系統; 5、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作償還由華潤醫藥控股發行的部分未償還債券; 6、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (4)
建银国际金融有限公司 CE AJO225 中国国际金融香港证券有限公司 CE AEN894 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198
Overall Coordinators (5)
中国国际金融香港证券有限公司 CE AEN894 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198 建银国际金融有限公司 CE AJO225 Morgan Stanley Asia Limited CE AAD291
Joint Bookrunners (14)
中国国际金融香港证券有限公司 CE AEN894 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198 建银国际金融有限公司 CE AJO225 Morgan Stanley Asia Limited CE AAD291 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615 香港上海汇丰银行有限公司 CE AAA523 MIZUHO SECURITIES ASIA LIMITED CE AEZ953 中信建投(国际)融资有限公司 CE BAU112 中银国际亚洲有限公司 CE AET863 招银国际融资有限公司 CE AVM940 农银国际融资有限公司 CE AWL249 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Joint Lead Managers (14)
中国国际金融香港证券有限公司 CE AEN894 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198 建银国际金融有限公司 CE AJO225 Morgan Stanley Asia Limited CE AAD291 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 香港上海汇丰银行有限公司 CE AAA523 MIZUHO SECURITIES ASIA LIMITED CE AEZ953 中信建投(国际)融资有限公司 CE BAU112 中银国际亚洲有限公司 CE AET863 招银国际融资有限公司 CE AVM940 农银国际证券有限公司 CE ACX411 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 High Action Limited 233,997,400 HKD — 0.42% — 6 months 2017-04-28
2 London International Trading (Asia) Limited 387,905,700 HKD — 0.69% — 6 months 2017-04-28
3 Nordea Investment Management AB 699,999,300 HKD — 1.25% — 6 months 2017-04-28
4 安邦投资控股有限公司 379,433,600 HKD — 0.68% — 6 months 2017-04-28
5 富士胶片公司 819,996,450 HKD — 1.46% — 6 months 2017-04-28
6 恒健国际投资控股(香港)有限公司 2,637,953,500 HKD — 4.70% — 6 months 2017-04-28
7 中国诚通控股集团有限公司 387,933,000 HKD — 0.69% — 6 months 2017-04-28
8 中国人寿保险(集团)公司 1,551,732,000 HKD — 2.76% — 6 months 2017-04-28

Directors & Management

PositionChinese nameEnglish Name
Chairman白曉松—
Company Secretary溫詠宜—
No director data available.

Major Shareholders

Major Shareholders & Holdings華潤集團(醫藥)直接持有54.00%,北京醫藥投資直接持有17.74%,北京國管中心合計持有21.00%(假設超額配股權並無獲行使)。
About this page

This page shows Chinares Pharma (03320) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect